At this year’s PMWS Pharma Manufacturing World Summit, Ripple Effect Communications’ Valerie Harding assisted with eschbach and LLumin’s workshop. It was a great event for pharma executives because this PMWS 24 workshop showed how shift communications integrated with preventive maintenance and asset management can improve product quality, enhance regulatory compliance and improve safety.
Andreas Eschbach was thrilled to showcase the ease of integrating Shiftconnector with other data applications to allow operators in pharma facilities to quickly resolve issues more efficiently. Coupled with this was the importance of preventive maintenance and asset management to achieve continuous improvement and reduce MTTR levels.
LLumin’s CMMS+ combined with Shiftconnector demonstrated how prompt and precise communications to teams can delivered on any critical manufacturing deviations before they escalate into major instrumentation and equipment breakdowns. The team demonstrated how the LLumin/eschbach combined solution helps keep production lines running smoothly and streamlined. Additionally, they showed that the system minimizes unplanned downtime, which can be extremely costly. They illustrated how they were able to optimize parameter conditions to maintain consistent product quality in complex drug manufacturing.
The Pharma Manufacturing World Summit brought together the senior executives making the big decisions for high-level strategic discussions that are shaping the future of their industry.
Photo: Andreas Eschbach, Valerie Harding, Felix Monschein, Dennis Ladd
As the global pharmaceutical industry continues to grow and evolve, companies are constantly facing pressures to focus on the patient as they improve the quality, efficacy, cost, and compliance of their life-saving products. A steady march of innovative large and small products is steadily coming into commercial production. A whole new generation of medicine is also on the way. Advanced Therapy Medicinal Products (ATMPs) including Cell and Gene Therapies (CGTs), are at the brink of creating the next and perhaps biggest industry sector pharmaceuticals have ever seen, and important decisions are being made right now about how today’s brightest minds are going to contribute to the shaping and maturing of this exciting and emerging new range of patient-saving breakthroughs.